Bidding War Ends as Inverness Plans to Acquire Biosite for $92.50 a Share

May 18, 2007

NEW YORK (GenomeWeb News) — Inverness Medical Innovations will buy Biosite after Beckman Coulter bowed out of the companies' protracted bidding war, Inverness said late yesterday on its Web site.

Under the purchase agreement, which comes after more than six weeks of offers, counteroffers, and negotiations, Inverness will pay $92.50 a share for 95 percent of Biosite's outstanding shares. Inverness already owns 5 percent.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Varied Opinions

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

Marine Mammal Gene Loss

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

Cell Count

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

This Week in PNAS

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.

Main menu